European Medicines Agency gives advice on the use of non-steroidal anti-inflammatories for COVID-19

News Category: Regulatory news

Date: 18/03/2020

The European Medicines Agency (EMA) has issued advice today following recent reports, especially on social media, which raise questions about whether non-steroidal anti-inflammatory medicines (NSAIDs) such as ibuprofen could worsen coronavirus disease (COVID-19). 

The EMA has confirmed that there is currently no scientific evidence establishing a link between ibuprofen and worsening of COVID-19. It is monitoring the situation closely and will review any new information that becomes available on this issue in the context of the pandemic.

Further details are available on the EMA website. This follows similar advice issued by the HPRA on Monday (16 March). Any changes to the regulatory position will be published on the HPRA website. The HSE has also published advice on this matter for members of the public on its website. Healthcare professionals should refer to the HSE website for up-to-date clinical guidelines.

« Back